LONDON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Today, LumiraDx Limited (Nasdaq: LMDX) a next-generation point of care diagnostics company, in partnership the British In Vitro Diagnostics Association, released the Testing Times report which outlines the role of rapid diagnostics in tackling antimicrobial resistance (AMR) and identifies barriers to their uptake in primary and community care.


NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.